Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients with High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma, and Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients with High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma, and Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KT-253 (Primary)
  • Indications Acute myeloid leukaemia; Adenoid cystic carcinoma; Fibrosarcoma; Lymphoma; Malignant melanoma; Merkel cell carcinoma; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Kymera Therapeutics

Most Recent Events

  • 27 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 04 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Jun 2024 Results (as of 26 January 2024,n= 18 pts) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top